Integer Holdings Corporation (NYSE:ITGR) Receives Average Rating of “Moderate Buy” from Brokerages

Integer Holdings Corporation (NYSE:ITGR) has been assigned an average recommendation of “Moderate Buy” from the thirteen analysts that are presently covering the firm, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a hold recommendation, five have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $97.00.

ITGR has been the topic of a number of recent research reports. Piper Sandler reiterated an “overweight” rating and issued a $97.00 target price (up from $87.00) on shares of Integer in a research note on Friday, May 1st. Freedom Capital upgraded shares of Integer to a “strong-buy” rating in a research report on Wednesday, July 22nd. Truist Financial increased their price objective on shares of Integer from $97.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, July 16th. Citigroup lifted their price objective on shares of Integer from $92.00 to $96.00 and gave the company a “neutral” rating in a research report on Wednesday, July 8th. Finally, Zacks Research raised shares of Integer from a “strong sell” rating to a “hold” rating in a research note on Monday, July 20th.

Integer Stock Performance

Shares of ITGR stock opened at $99.66 on Friday. The company has a market cap of $3.38 billion, a P/E ratio of 24.85, a PEG ratio of 2.39 and a beta of 0.64. The business has a 50 day moving average of $93.02 and a two-hundred day moving average of $88.60. Integer has a 52 week low of $62.00 and a 52 week high of $111.99. The company has a quick ratio of 2.38, a current ratio of 3.75 and a debt-to-equity ratio of 0.77.

Integer (NYSE:ITGR) last released its quarterly earnings data on Thursday, April 30th. The medical equipment provider reported $1.20 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.21 by ($0.01). The company had revenue of $439.58 million for the quarter, compared to analyst estimates of $426.48 million. Integer had a net margin of 7.64% and a return on equity of 12.83%. The company’s revenue for the quarter was up .5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.31 EPS. As a group, analysts anticipate that Integer will post 6.04 EPS for the current year.

Institutional Investors Weigh In On Integer

A number of institutional investors and hedge funds have recently bought and sold shares of ITGR. Salomon & Ludwin LLC boosted its position in shares of Integer by 46.8% during the 4th quarter. Salomon & Ludwin LLC now owns 370 shares of the medical equipment provider’s stock valued at $29,000 after purchasing an additional 118 shares in the last quarter. EverSource Wealth Advisors LLC boosted its holdings in Integer by 48.1% during the first quarter. EverSource Wealth Advisors LLC now owns 360 shares of the medical equipment provider’s stock worth $32,000 after buying an additional 117 shares in the last quarter. TD Private Client Wealth LLC boosted its holdings in Integer by 1,037.5% during the fourth quarter. TD Private Client Wealth LLC now owns 455 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 415 shares in the last quarter. Parkside Financial Bank & Trust grew its position in Integer by 135.5% in the fourth quarter. Parkside Financial Bank & Trust now owns 464 shares of the medical equipment provider’s stock worth $36,000 after buying an additional 267 shares during the last quarter. Finally, Arax Advisory Partners grew its position in Integer by 2,489.5% in the fourth quarter. Arax Advisory Partners now owns 492 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 473 shares during the last quarter. 99.29% of the stock is owned by institutional investors and hedge funds.

Integer Company Profile

Integer Holdings Corporation (NYSE: ITGR) is a global provider of outsourced medical device design, development and manufacturing solutions. The company partners with leading medical technology firms to deliver complex components, subsystems and finished devices across a range of therapeutic areas. Its services encompass concept and product design, precision machining, microelectronic assembly, terminal sterilization and regulatory support, enabling customers to accelerate time to market and optimize product performance.

Integer’s product portfolio is organized into two core segments: Advanced Delivery and MedTech.